重大事件
即時報告
8-K
2026-07-24
Daré Bioscience 提交 8-K 披露最新公司簡報 聚焦女性健康產品管線與策略
AI 繁中摘要
📄 Daré Bioscience 提交 8-K 披露最新公司簡報
申報類型：8-K（重大事件報告）
報告日期：2026年7月24日
公司：Daré Bioscience, Inc.（納斯達克代碼：DARE）
Daré Bioscience 於本日向 SEC 提交 8-K 表格，主要內容為根據 Regulation FD 披露一項公司簡報（Corporate Presentation），日期為 2026年7月24日。該簡報將用於與證券市場參與者及其他相關方的會議，即日起生效。
簡報內容涵蓋公司最新業務進展、產品管線及策略願景，但本次 8-K 並未提供具體財務數字或營運成果。公司計劃將該簡報上載至其投資者關係網站（https://ir.darebioscience.com）的「Presentations, Events & Webcasts」頁面。
需要留意的是，此項資訊屬「提供」（furnished）而非「存檔」（filed），因此不會被視為根據《1934年證券交易法》第18條的申報文件，亦不會被納入其他 SEC 申報文件中（除非公司明確以引用方式納入）。
對於投資者而言，這份簡報可能揭示 Daré 在女性健康領域（如避孕、陰道健康等）的臨床進展或商業化計劃，建議投資者自行查閱簡報原文以評估潛在影響。由於簡報內容屬自願性披露，不構成對未來業績的預測或保證。
展開英文正文
false 0001401914 0001401914 2026-07-24 2026-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2026 DARE BIOSCIENCE, INC. DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 3655 Nobel Drive, Suite 260 San Diego, CA 92122 (Address of Principal Executive Offices and Zip Code) Registrant’s telephone number, including area code: (858) 926-7655 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock DARE Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01 Regulation FD Disclosure. Furnished as Exhibit 99.1 to this report is a copy of a corporate presentation of Daré Bioscience, Inc. (“Daré” or the “Company”) dated July 24, 2026, which is incorporated herein by reference. The Company intends to use the presentation and its contents in various meetings with securities market participants and others, commencing on July 24, 2026. The Company plans to make a copy of the presentation available in the “Investors” section of its website (https://ir.darebioscience.com), on the page titled “Presentations, Events & Webcasts,” under the heading “Presentations.” Information contained in, or that can be accessed through, the Company’s website or any other website referenced in the presentation is not incorporated by reference into this report. The information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Daré Bioscience corporate presentation, dated July 24, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -2- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DARÉ BIOSCIENCE, INC. Dated: July 24, 2026 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -3-